Islet Autoantibody Screening Throughout Australia Using In-Home Blood Spot Sampling: 2-Year Outcomes of Type1Screen
Authors' conclusion
Type1Screen has national reach. In-home blood spot screening is feasible, particularly for younger participants living regionally, and identifies the expected prevalence of preclinical T1D. The lower cost, increased convenience, and greater reach of blood spot screening could help meet increasing demand for early T1D diagnosis.
Study context
- Population
- Australians with a family history of T1D registered in Type1Screen, July 2022–June 20241,243 tested
- Participants
- 2,064 participants
- Exposure
- In-home blood spot vs venipuncture islet autoantibody screening
- Blood spotn = 1,507
- Venipuncturen = 557reference
- Outcome
- Prevalence of islet autoantibodies
Methodological detailsnational, in-home capillary blood spot sampling vs venipuncture
- National
- In-home capillary blood spot sampling vs venipuncture
Main finding
As reported in the abstract
Multiple autoantibodies
Single autoantibody
- Positive screening test
- 72 participants (5.9%)
Observational data: associations, not effects.
Further findings
Age of registrants · lower with Blood spot
P < 0.0001
Living in regional Australia · higher with Blood spot
P = 0.0037
Events
| Outcome | Blood spot | Venipuncture |
|---|---|---|
| Unsuccessful sample collection | 1 | 5 |
Clinical diabetes
- Developed clinical diabetes
- 12 participants
- All had screened positive
Safety
Diabetic ketoacidosis (DKA) at diabetes diagnosis
- DKA among 12 participants who developed clinical diabetes
- 0
Original publication
Islet Autoantibody Screening Throughout Australia Using In-Home Blood Spot Sampling: 2-Year Outcomes of Type1Screen. Diabetes Care. Published 29 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →